



NDA 021588/S-045
NDA 021588/S-046

**SUPPLEMENT APPROVAL
POSTMARKETING COMMITMENT FULFILLMENT**

Novartis Pharmaceuticals Corporation
Attention: Omer Munir, RPh
Senior Associate Director, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Mr. Munir:

Please refer to your Supplemental New Drug Applications (sNDAs) dated February 5, 2016 (S-045) and February 26, 2016 (S-046), received February 5 and 26, 2016 respectfully, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for GLEEVEC[®] (imatinib mesylate) Tablets, 100 and 400 mg.

These Prior Approval supplemental new drug applications provide for the following changes to the Prescribing Information:

Supplement S-045: Updates to include language that references the two FDA-approved companion diagnostic tests for patients with aggressive systemic mastocytosis (ASM) and myelodysplastic/myeloproliferative diseases (MDS/MPD).

Supplement S-046: Conversion of the prescribing information in accordance with the Pregnancy and Lactation Labeling Rule (PLLR).

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENTS

We have received your submissions dated February 5 and 25, 2016, reporting on the following postmarketing commitments listed in the March 25, 2011 postmarketing commitment letter.

PMC 154-2: To develop, in consultation with CDRH, a validated test kit for PDGFR gene rearrangements for patients with MDS/MPD.

Meet with CDRH: by October 15, 2011

Protocol submission date: Not Applicable

Study completion date: Not Applicable

Final report submission date: Diagnostic test to be filed under a Humanitarian Device Exemption (HDE) by April 15, 2013

PMC 650-2: To develop, in consultation with CDRH, a validated test kit for D816V c-kit mutation in aggressive systemic mastocytosis.

Meet with CDRH: by October 15, 2011

Protocol submission date: Not Applicable

Study completion date: Not Applicable

Final report submission date: Diagnostic test to be filed under an HDE by April 15, 2013 (If test cannot be developed under an HDE, the applicant will meet with the Division and CDRH within 3 months of April 15, 2013 to identify next steps.)

We have reviewed your submission and conclude that the above commitments were fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our March 25, 2011, letter.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Natasha Kormanik, Regulatory Health Project Manager, at (240)402-4227.

Sincerely,

{See appended electronic signature page}

Ann T. Farrell, MD
Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANN T FARRELL
08/25/2016